StockData
Bright Minds Biosciences Inc. logo

Bright Minds Biosciences Inc. (DRUG) company profile

DRUGNasdaqPharmaceutical PreparationsFiscal year ends September 30
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Sep 30, 2025Last filing: 40-F on Dec 23, 2025Score 5/30
$20.76+0.25 (+1.22%)

Close on Nov 18, 2026Market cap $158.52MP/E –Yield –

About Bright Minds Biosciences

Pharmaceutical Preparations, SIC 2834

Bright Minds Biosciences Inc. operates as a Canadian biotechnology and pharmaceutical company classified under pharmaceutical preparations. The provided text indicates that the enterprise conducts its activities alongside wholly owned subsidiaries. However, specific operational segments, proprietary therapeutic products or clinical pipeline assets, distinct commercial services, and identified customer groups are not detailed within the excerpted filing text. The entity focuses on administrative, governance, and regulatory compliance functions necessary for maintaining public reporting requirements across relevant capital oversight frameworks.

In terms of geographic footprint and scale, the business maintains dual corporate headquarters situated in North America. Its Canadian corporate headquarters is located in Vancouver, British Columbia, representing the jurisdiction where the organization is incorporated. Additionally, the company operates a United States corporate headquarters based in Chicago, Illinois, while also designating an agent for service in New York, New York. Further details concerning workforce size, laboratory facilities, or broader operational locations are not specified.

Summary of the business section of Bright Minds Biosciences's latest annual report, written by StockData.

Company profile

Company

Legal name
Bright Minds Biosciences Inc.
Headquarters
Chicago, IL
Address
400 N Aberdeen St Suite 900 60642
Phone
(647) 407-2515
Employees
1, Sep 30, 2024
Industry
Pharmaceutical Preparations
Incorporated in
A1
Fiscal year ends
September 30
Auditor
De Visser Gray LLP, Vancouver, Canada

Stock & identifiers

Ticker
DRUG
Exchange
Nasdaq
IPO date
Mar 22, 2021
Shares outstanding
8M, Sep 30, 2025
Filer category
<br>Emerging growth company
Stock splits
1-for-5 reverse, Dec 29, 2023; 1-for-5 reverse, Jul 14, 2023
SEC CIK
1827401
CUSIP
10919W405
ISIN
CA10919W4056
FIGI
BBG00ZKX9FP7
Share class FIGI
BBG00Z61F382
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

No recent ownership filings by officers or directors

Bright Minds Biosciences's leadership is listed in its proxy statement (Form DEF 14A).

Employees

Headcount reported in annual reports

“However, the Company's wholly-owned subsidiary, Bright Minds Biosciences LLC, has one employee.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?